| Cat.No. | Name | Information |
|---|---|---|
| M14523 | DASA-58 | DASA-58 is a potent activator of pyruvate kinase M2 (PKM2) with an AC90 of 680 nM, and an AC50 of 38 nM. |
| M9034 | Mitapivat (AG-348) | Mitapivat (AG-348) is the first-in-class, oral effective pyruvate kinase small molecule allosteric activator. Mitapivat (AG-348) is active against wild-type and various mutated PKR enzymes, and promotes healthy red blood cell generation by activating mutated PKR to increase ATP levels. |
| M9001 | ML-265 (TEPP-46) | Ml-265 (TEPP-46) is an effective activator of pyruvate kinase M2 (PKM2). |
| M6261 | PKM2 inhibitor | PKM2 inhibitor displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2. |
| M2865 | Sodium Monofluorophosphate | Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively, which also irreversibly inhibits phosphorylase phosphatase with Ki of 0.5 mM. |
| M42596 | ZY-1 | ZY-1 is a control molecule of ZY-2. |
| M42595 | PKR activator 4 | PKR activator 4 is a potent pyruvate kinase R (PKR) activator. |
| M42594 | CIAC001 | CIAC001 is a Pyruvate Kinase PKM2 inhibitor with anti-neuroinflammatory activity. |
| M42593 | PKM2/PDK1-IN-1 | PKM2/PDK1-IN-1, one of shikonin thioether derivatives, is a dual inhibitor of PKM2/PDK1. |
| M42592 | PKM2-IN-4 | Pkm2-in-4 is a selective inhibitor of PKM2 (IC50=0.35 μM), which regulates pyruvate-dependent respiration and induces mitochondrial H202 production rate and electron transport system coupling. |
| M31416 | TP-1454 | TP-1454 is an activator of PKM2 and can be used in studies related to solid tumors. |
| M31415 | AG-946 | AG-946 is an orally active pyruvate kinase (PK) variant activator for studies related to sickle cell anemia and myelodysplastic syndromes. |
| M31414 | Melarsoprol | Melarsoprol is a triazine analog that also acts as a PKLR/PKM2 modulator and can be used in studies related to African trypanosomiasis. |
| M21076 | Etavopivat | Etavopivat, an oral erythrocyte pyruvate kinase activator, is being developed for sickle cell disease and other hemoglobinopathies, previously reported in 2019. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
